

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A method for treating headache comprising administering to a subject in need of headache relief, an effective amount of a compound selected from the group consisting of loxapine, pharmaceutically acceptable salts of loxapine, and prodrugs of loxapine wherein 0.3 to 6.0 mg of loxapine is administered, or an amount of a salt or prodrug of loxapine is administered that produces in the subject a blood concentration of loxapine equivalent to the administration of 0.3 to about 6.0 mg of loxapine.

2-4. (Cancelled)

5. (Previously Presented) A method in accordance with claim 1, wherein said headache is a migraine headache.

6. (Previously Presented) A method in accordance with claim 1, wherein said headache is a cluster headache.

7. (Previously Presented) A method in accordance with claim 1, wherein said headache is a tension-type headache.

8. (Previously Presented) A method in accordance with claim 1, wherein said compound is administered by inhalation.

9. (Previously Presented) A method in accordance with claim 1, wherein said subject is human, said headache is a migraine headache, and said compound is administered by inhalation.

10. (Cancelled)

11. (Cancelled)

12. (Previously Presented) A method in accordance with claim 1, wherein the compound is formulated so as to result in a maximum blood level of loxapine within about 30 minutes from administration.

13. (Previously Presented) A method in accordance with claim 1, wherein the compound is formulated so as to result in a maximum blood level of loxapine within about 15 minutes from administration.

14. (Previously Presented) A method in accordance with claim 1, wherein the compound is formulated so as to result in a peak rate of increase in the blood level of loxapine of at least about 1 ng/ml/minute.

15. (Previously Presented) A method in accordance with claim 1, wherein the compound is formulated so as to result in a blood level of loxapine of at least about 5 ng/ml within about 15 minutes from administration.

16. (Previously Presented) A method in accordance with claim 1, wherein said compound is administered via inhalation using a rapid-heating drug delivery article or a thin-film drug delivery article.

17. (Previously Presented) A method in accordance with claim 1, wherein said compound is administered via an inhalation delivery device, wherein said compound is

vaporized and condensed to provide at least 50% recovery of said compound in an aerosol, and wherein said aerosol contains less than about 5% by weight of compound degradation products.

18. (Previously Presented) A method in accordance with claim 17, wherein said compound is coated on a substrate in the delivery device as a film having a thickness between about 0.5 and 20 μm .

19. (Previously Presented) A method in accordance with claim 1, wherein said compound is administered in the form of an aerosol having a mass median aerodynamic diameter of between about 0.01 and about 3 μm .

20. (Previously Presented) A method in accordance with claim 1, wherein said compound is administered via a rapid heating drug delivery article, and wherein said compound is volatized from a compound composition film under conditions sufficient to provide an aerosol having at least 50% recovery of said compound and containing less than about 10% by weight of compound degradation products.

21. (Withdrawn) A composition for the treatment of headache, said composition comprising (a) an effective amount of a compound selected from the group consisting of loxapine, pharmaceutically acceptable salts thereof, and prodrugs thereof, and (b) a pharmaceutically acceptable carrier.

22. (Withdrawn) A composition of claim 21, further comprising one or more analgesic, anti-inflammatory or antimigraine agents.

23. (Withdrawn) A thin-film composition for the treatment of headache comprising an effective amount of a compound selected from the group consisting of loxapine, pharmaceutically acceptable salts thereof and prodrugs thereof, and having a film thickness of from about 0.5 to about 20 μm .

24. (Currently amended) A method for treating headache pain in a subject comprising administering to said subject an effective amount of a compound selected from the group consisting of loxapine, pharmaceutically acceptable salts of loxapine and prodrugs of loxapine wherein 0.3 to 6.0 mg of loxapine is administered, or an amount of a salt or prodrug of loxapine is administered that produces in the subject a blood concentration of loxapine equivalent to the administration of 0.3 to about 6.0 mg of loxapine.